Netspot gallium-68 dotatate

The Regional Health Contracting Office - Pacific, in support of Tripler Army Medical Center, Hawaii, intends to make a sole source award to Advanced Accelerator Applications USA, Inc. for gallium-68 dotatate (brand name: Netspot®), a radiopharmaceutical injection kit that is FDA-approved to be used for detection of neuroendocrine tumors (NETs) using Positron Emission Tomography (PET) scans. The contract is anticipated to be a 7-month base period plus two 12-month option periods.

The statutory authority permitting this award without providing full and open competition is FAR 13.106-1(b)(1)(i), which authorizes the government to award contracts when the circumstances of the contract action deem only one source reasonably available and no other suppliers or services will satisfy agency requirements.

This announcement fulfills the synopsis requirements under FAR 5.201 and 5.203. This Notice of Intent is not a request for competitive quotes. All responsible sources may submit a capability statement, which shall be considered by the agency before the intended award date.

Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to supply the required products. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. No proprietary, classified, confidential, or sensitive information should be included in your response.